Key result
Long-term use of angiotensin receptor blockers was associated with incident cancer (OR 1.12; 95% CI 1.06-1.18), though similar small risk increases were seen across all antihypertensive classes.
Why the study?
Does long-term use of drugs affecting the renin-angiotensin system increase the risk of cancer compared to other antihypertensives?
Population
149,417 incident cancer cases and 4 age- and gender-matched controls per case in Denmark during the period…
Comparison
Long-term use of angiotensin receptor blockers… vs Users of other antihypertensives and non-users.
Design
Case-control
Follow-up
5 years (2000-2005)
Authors
Loading...
Small cancer risk with long-term ARBs matches other antihypertensives and should not change practice; leaves open confounding by indication in observational data.
Case-Control (n=747,085)
Does long-term use of drugs affecting the renin-angiotensin system increase the risk of cancer compared to other antihypertensives?
Odds Ratio: 1.12 (95% CI 1.06–1.18)
Long-term use of ARBs and ACEIs does not appear to carry a higher risk of cancer than other antihypertensive drugs, suggesting that the small observed risk increase is likely related to the underlying indication for treatment.
Hallas et al. (2012) conducted a case-control in Incident cancer (n=747,085). Long-term use of angiotensin receptor blockers (ARBs) vs. Matched controls was evaluated on Incident cancer (OR 1.12, 95% CI 1.06-1.18). Long-term use of angiotensin receptor blockers was associated with incident cancer (OR 1.12; 95% CI 1.06-1.18), though similar small risk increases were seen across all antihypertensive classes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: